Ankylosing spondylitis - adalimumab, etanercept and infliximab: review proposal - November 2010
Proposal to defer the review
The planned date for review of the above guidance was October 2010.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.
Consequently we propose that consideration of the review of the original guidance be deferred until the ongoing single technology appraisal of golimumab for the treatment of ankylosing spondylitisis considered for review
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 02 December 2010